CL2020002550A1 - Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.

Info

Publication number
CL2020002550A1
CL2020002550A1 CL2020002550A CL2020002550A CL2020002550A1 CL 2020002550 A1 CL2020002550 A1 CL 2020002550A1 CL 2020002550 A CL2020002550 A CL 2020002550A CL 2020002550 A CL2020002550 A CL 2020002550A CL 2020002550 A1 CL2020002550 A1 CL 2020002550A1
Authority
CL
Chile
Prior art keywords
pharmaceutical use
pyrazole compounds
heteroaryl substituted
substituted pyrazole
pharmaceutical
Prior art date
Application number
CL2020002550A
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2020002550A1 publication Critical patent/CL2020002550A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de pirazol sustituidos con heteroarilo o sus sales farmacéuticamente<br /> aceptables que tienen una actividad inhibidora de SGLT1 y son útiles para un fármaco, composiciones farmacéuticas que lo comprenden, y su uso farmacéutico; específicamente, un compuesto de fórmula [X]:<br /> en donde R1 es hidrógeno o halógeno, R2 es alquilo de C1-6 o haloalquilo de C1-6, el anillo Het es piridilo sustituido o pirazinilo, pirimidinilo o piridazinilo opcionalmente sustituido, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y su uso farmacéutico se proporciona.
CL2020002550A 2018-04-04 2020-10-01 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. CL2020002550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04

Publications (1)

Publication Number Publication Date
CL2020002550A1 true CL2020002550A1 (es) 2021-01-15

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002550A CL2020002550A1 (es) 2018-04-04 2020-10-01 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.

Country Status (20)

Country Link
US (3) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR102806676B1 (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686B2 (es)
MX (1) MX2020010433A (es)
MY (1) MY206359A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
AR114465A1 (es) * 2018-04-04 2020-09-09 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica
KR20220057562A (ko) * 2019-09-04 2022-05-09 니뽄 다바코 산교 가부시키가이샤 만성 신장병의 치료 또는 예방 방법
WO2021045159A1 (ja) * 2019-09-04 2021-03-11 日本たばこ産業株式会社 併用医薬による糖尿病の治療又は予防方法
WO2021187548A1 (ja) * 2020-03-19 2021-09-23 日本たばこ産業株式会社 慢性心不全の治療又は予防方法
WO2025249555A1 (en) * 2024-05-31 2025-12-04 Japan Tobacco Inc. Method for treating or preventing hypertrophic cardiomyopathy
WO2025255096A1 (en) * 2024-06-03 2025-12-11 Dana-Farber Cancer Institute, Inc. Cycloalkyl and heterocyclic modulators of tnf activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
PL377848A1 (pl) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1889842A4 (en) 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
AU2007219509A1 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
JP2010505957A (ja) 2006-10-10 2010-02-25 アムゲン インコーポレイティッド 糖尿病に対して使用されるｎ−アリールピラゾール化合物
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP4994295B2 (ja) 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
JP2012523405A (ja) * 2009-04-10 2012-10-04 ファイザー・インク ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
WO2011161615A1 (en) 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
DE102011055815A1 (de) * 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
DE102012016908A1 (de) * 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2016050921A1 (en) * 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
PE20170693A1 (es) * 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
EP3263567A1 (en) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
AR114465A1 (es) * 2018-04-04 2020-09-09 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica

Also Published As

Publication number Publication date
TW201942114A (zh) 2019-11-01
KR102806676B1 (ko) 2025-05-13
JP2019182852A (ja) 2019-10-24
CN111902408B (zh) 2023-11-14
JP2022166280A (ja) 2022-11-01
US20240166632A1 (en) 2024-05-23
US20220048896A1 (en) 2022-02-17
AU2019249560A1 (en) 2020-07-23
CO2020012353A2 (es) 2021-01-18
BR112020019939A2 (pt) 2021-01-05
MY206359A (en) 2024-12-12
ZA202006053B (en) 2022-03-30
PH12020551624A1 (en) 2021-07-12
IL277686B1 (en) 2024-07-01
US10988462B2 (en) 2021-04-27
PE20201068A1 (es) 2020-10-19
JP7130588B2 (ja) 2022-09-05
WO2019194207A1 (ja) 2019-10-10
AR114465A1 (es) 2020-09-09
EP3778593A1 (en) 2021-02-17
CA3089092A1 (en) 2019-10-10
AU2019249560B2 (en) 2023-10-05
RU2020132318A (ru) 2022-04-29
IL277686B2 (en) 2024-11-01
JP2024050645A (ja) 2024-04-10
US20190330193A1 (en) 2019-10-31
MX2020010433A (es) 2020-10-28
KR20200139696A (ko) 2020-12-14
TWI805727B (zh) 2023-06-21
SG11202009179TA (en) 2020-10-29
EP3778593A4 (en) 2021-12-22
CN111902408A (zh) 2020-11-06
RU2020132318A3 (es) 2022-04-29
IL277686A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CO2020012353A2 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
MX2021009763A (es) Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
MX2018004008A (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
MX379536B (es) Compuestos de pirimidinio sustituido y derivados para combatir plagas de animales.
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
MX2018003993A (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
UY37941A (es) Derivados de bencimidazol y sus usos